FindTrial
Sign In

Remestemcel-L

BIOLOGICAL8 trials

Sponsors

Mesoblast, Inc., Mesoblast International Sàrl, Icahn School of Medicine at Mount Sinai, The Cleveland Clinic

Conditions

Acute Respiratory Distress SyndromeCOVIDCrohn ColitisGrade B Acute Graft Versus Host DiseaseGrade B aGVHDGrade C Acute Graft Versus Host DiseaseGrade C aGVHDGrade D Acute Graft Versus Host Disease

Phase 1

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
TerminatedNCT04543994
The Cleveland ClinicUlcerative Colitis
Start: 2020-11-10End: 2023-11-15Updated: 2026-04-16
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
TerminatedNCT04548583
The Cleveland ClinicCrohn Colitis
Start: 2020-11-04End: 2023-11-15Updated: 2026-04-16

Phase 3

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
CompletedNCT02336230
Mesoblast, Inc.Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
Start: 2015-06-04End: 2018-04-09Updated: 2022-03-17
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
CompletedNCT02652130
Mesoblast, Inc.Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
Start: 2015-10-28End: 2018-06-15Updated: 2022-03-16
MSCs in COVID-19 ARDS
TerminatedNCT04371393
Icahn School of Medicine at Mount SinaiAcute Respiratory Distress Syndrome, COVID, Mesenchymal Stromal Cells +1
Start: 2020-04-30End: 2022-01-02Updated: 2022-04-25

Unknown Phase

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
NCT00759018
Mesoblast, Inc.Graft-Versus-Host Disease, Graft vs Host Disease
Updated: 2020-03-09
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
NCT04366830
Mesoblast International SàrlModerate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Updated: 2021-02-18
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
NCT04456439
Mesoblast International SàrlMultisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Updated: 2025-10-31

Related Papers

Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis
Blood2020-11-051 citations
Effect of Remestemcel-L Treatment in Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Biomarker Substudy
Blood2020-11-041 citations
Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children
Biology of Blood and Marrow Transplantation2020-02-0763 citations
A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
2020-02-01127 citations
A Phase 3 Single-Arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Steroid Refractory Acute Gvhd in Pediatric Patients
Biology of Blood and Marrow Transplantation2018-02-038 citations
Effect of Human Mesenchymal Stem Cells (Remestemcel-L) on Clinical Response and Survival Confirmed in a Large Cohort of Pediatric Patients with Severe High-Risk Steroid-Refractory Acute Graft Versus Host Disease
Biology of Blood and Marrow Transplantation2016-02-183 citations